NCT02558348View on ClinicalTrials.gov

Phase 1/2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001)

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

February 14, 2017

Study Completion Date

May 30, 2017

Conditions
Endometrial CancerOvarian CancerCervical Cancer
Interventions
DRUG

AL3818

Administered orally

Trial Locations (2)

60637

University of Chicago Medical Center, Chicago

84112

Huntsman Cancer Institute, University of Utah, Salt Lake City

Sponsors
All Listed Sponsors
lead

Advenchen Laboratories, LLC

INDUSTRY